Distinguished Professor, Director, Institute Head
| Professor Wen-Pin Su graduated from the School of Medicine, College of Medicine, National Taiwan University, and obtained his PhD from the Institute of Clinical Medicine, National Cheng Kung University. He is currently a distinguished professor and the director of the Institute of Clinical Medicine at National Cheng Kung University (NCKU) and the director of the Clinical Medicine Research Center at National Cheng Kung University Hospital (NCKUH). Professor Su is also a clinical oncologist and a professor at the Departments of Oncology and Urology, School of Medicine at NCKU. He is also a member of the Center of Applied Nanomedicine, NCKU.
In addition to his daily work on outpatient diagnosis, treatment, and inpatient medical services for cancer patients, he is also actively involved in the “Taiwan Clinical Trial Consortium- Genitourinary Cancer” and numerous phase III global clinical trials and has been invited to publish co-author papers in the top international journals, such as “Lancet” and “Lancet Oncology.” He has received twice the “Top International Journal Awards” from National Cheng Kung University. Professor Su also participates in early-phase clinical trials in cancer treatment, including first-in-human phase I international clinical trials. Additionally, he serves as a review committee member for cancer diagnostic tests and laboratory-developed tests (LDTs) and as a member of the National Health Service’s Cancer Prevention and Treatment Review Committee. Regarding his research, Professor Su focuses on utilizing nano-platforms and extracellular vesicles (exosomes) to modulate the tumor microenvironment, thereby enhancing the efficacy of cancer immunotherapy. He also concentrates on DNA repair mechanisms to address drug resistance issues in clinical cancer treatment. Since 2021, Professor Su has published nine corresponding author papers in journals with Impact Factors exceeding 10 (e.g., Nano Today, ACS Nano, Nucleic Acids Research, Nature Communications, Journal of Nanobiotechnology), with five of these papers achieving Impact Factors over 15, demonstrating his prolific research output. In 2021, he was nominated for the “Future Technology Award” shortlisted. In 2023, he received “Dr. Chien-Tien Hsu’s Outstanding Cancer Research Award” from the Taiwan Oncology Society. In 2024, he was awarded the “Excellence in Academic Research Grant – Publication in the Top 5% of Academic Fields” by NCKU. He is also honored with the “National Innovation Award of Taiwan Government- Academic and Research Innovation” in 2024. In 2025, he also won “Year paper in Medical Campus, NCKU,” “Future Technology Award” and “National Innovation Award of Taiwan Government- Academic and Research Innovation.” Professor Su, as a seasoned oncologist with extensive experience in clinical trials for novel cancer therapeutics. He bridges nanotechnology platforms with microscopic research to pioneer novel cancer treatment approaches. From the 2018 Nobel Prize in Physiology or Medicine awarded to researchers studying CTLA-4 and PD-1/PD-L1, to the 2019 prize recognizing the discovery of hypoxia mechanisms, and the 2025 award for metal-organic framework nanomaterials, these accolades confirm that nanotechnology applications in biomedicine align with global trends. We aim to contribute significantly to the development, research, and treatment of novel cancer therapies. |